Connecticut Medicaid P&T Meeting Minutes June 5, 2008
|
|
- Austin Goodwin
- 5 years ago
- Views:
Transcription
1 Connecticut Medicaid P&T Meeting Minutes June 5, 2008 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Kenneth Marcus, MD Lester Silberman, MD Peggy Manning Memoli, Pharm D Richard T. Carbray, Jr., RPh Steven Marcham RPh Lawrence Sobel, RPh Absent Members: Stella Cretella Bennett Enowitch, MD Charles Thompson, MD DSS: Evelyn Dudley Herman Kranc Robert Zavoski, MD MPH Jim Zakszewski Dan Butler EDS/Provider Synergies: Chris Andrews Ellen Arce Joy DeNardo Opening remarks: Dr. Sherter made the following announcements: Chris Andrews is still our Connecticut Clinical Account Manager from Provider Synergies. Dr. Lester Silberman is filling the vacancy for a Practicing Physician, Family Planning Specialist. Dr. Sherter introduced Dr. Silberman and asked him to give a brief biography. Dr. Silberman obliged and told committee members that he previously held the position of chief of OB-GYN at Danbury Hospital. He currently serves as the Medical Director for Planned Parenthood of CT. The election of officers for 2008 will be held tonight. The smoking cessation study would be discussed tonight. Election of Officers: Dr. Sherter announced that the committee needed to elect officers for the year. Steve Marcham motioned to re-elect the current slate of Dr. Carl Sherter as chairman and Dr. Peggy Memoli as vice-chair. Larry Sobel seconded that motion. The committee members voted and agreed that Dr. Sherter would be chairman and Dr. Memoli would be vice-chair for The motion passed unanimously. Approval of minutes: Committee members approved the meeting minutes from the March 20, 2008 meeting.
2 Smoking Cessation Study: The committee discussed the smoking cessation report, Plan for Treating Tobacco Use and Dependence, which was submitted to the Legislature in March The report summarized studies that conclude that smoking cessation products double the chances of successful smoking cessation. The committee members discussed the health benefits of smoking cessation and therefore the decreased medical costs. The committee members agreed that smoking cessation products should be covered by CT Medicaid. Steve Marcham motioned to add smoking cessation products as a class to the PDL, with Dr. Sherter seconding. The motion was passed unanimously. New Generics: Chris Andrews informed the committee members that there were no new generics to discuss. Therapeutic Class Reviews: Chris Andrews, from Provider Synergies, presented clinical data and financial analysis, as well as answered questions from committee members on the following eleven therapeutic classes. Outcomes and votes are recorded below by class: Analgesics, Narcotic Long-Acting that there were additional strengths now available for Kadian, Oxycontin, and Opana ER. The recommended change to this class would be the addition of fentanyl transdermal patches. Larry Sobel was concerned that by maintaining Oxycontin and oxycodone ER as non-preferred the committee may be limiting access to hospice and nursing home patients and serving as a policing agent. Dr. Sherter cited the ease of our Prior Authorization process for providers to obtain needed medication for their patients. Steve Marcham motioned to approve and accept Provider Synergies recommendations as presented with Dr. Marcus seconding. The motion was passed with Larry Sobel abstaining. Duragesic, fentanyl transdermal, Kadian, methadone, morphine ER Avinza, Opana ER, oxycodone ER, Oxycontin, Ultram ER Analgesics, Narcotic Short-Acting that the recommended changes to this class would be the addition of oxycodone/asa and oxycodone/ibuprofen. Steve Marcham motioned to approve and accept Provider Synergies recommendations as presented with Dr. Marcus seconding. The motion was passed unanimously. APAP/codeine, APAP/dihydrocodeine/caffeine, APAP/hydrocodone, APAP/oxycodone, APAP/pentazocine, APAP/propoxyphene, APAP/tramadol, ASA/codeine, ASA/oxycodone, butalbital compound/codeine, codeine, hydrocodone/ibuprofen, hydromorphone, meperidine, morphine IR, oxycodone/ibuprofen, oxycodone IR, propoxyphene, tramadol
3 Darvon-N, fentanyl buccal, Fentora, levorphanol, Opana, Panlor DC, pentazocine/naloxone Angiotensin Modulators that this class would now include the ACE inhibitors, ARBs (Angiotensin II Receptor Blockers) and Direct Renin Inhibitor. The recommended changes to this class would be the addition of ramipril and trandolapril (and the subsequent removal of their brand name products of Altace and Mavik respectively), and the removal of Cozaar and Hyzaar. Dr. Memoli questioned the reasoning behind the recommendation to remove Cozaar and Hyzaar. Chris Andrews cited that Cozaar and Hyzaar offered no clinical advantages over the other ARB products in this class to justify the price difference. Steve Marcham asked for clarification of the amount of savings that would be lost by keeping Cozaar and Hyzaar as preferred products, which Chris answered. Dr. Memoli motioned to approve and accept Provider Synergies recommendations with the addition of Cozaar and Hyzaar as preferred. Dr. Marcus seconded. The motion was passed unanimously. Avapro/Avalide, benazepril, benazepril/hctz, Benicar, Benicar HCT, captopril, captopril/hctz, Cozaar/Hyzaar, Diovan, Diovan HCT, enalapril, enalapril/hctz, fosinopril, fosinopril/hctz, lisinopril, lisinopril/hctz, Micardis, Micardis HCT, moexipril, moexipril/hctz, quinapril, quinapril/hctz, ramipril, trandolapril Aceon, Atacand/Atacand HCT, Tekturna/Tekturna HCT, Teveten/Teveten HCT Anticoagulants, Injectable that the recommended change to this class would be the removal of Innohep as preferred. Larry Sobel motioned to approve and accept Provider Synergies recommendations as presented with Dr. Marcus seconding. The motion was passed unanimously. Arixtra, Fragmin, Lovenox Innohep Atopic Dermatitis that the recommended change for this class would be the addition of Elidel as preferred. Dr. Silberman motioned to approve and accept Provider Synergies recommendations as presented with Larry Sobel seconding. The motion was passed unanimously. Elidel, Protopic None
4 Beta Blockers that Bystolic is the only new product in this class and that the recommended change for this class would be the addition of Coreg CR as preferred. Dr. Memoli questioned why Bystolic was not recommended as preferred, given the clinical information on its use in the African American population. Dr. Sherter pointed out that the current utilization was 1 prescription and cited the ease of our Prior Authorization process for providers to obtain needed medication for their patients. Dr. Marcus inquired when this class would be reviewed again. Dr. Sherter replied that this class would be reviewed again in one year. Steve Marcham motioned to approve and accept Provider Synergies recommendations as presented with Richard Carbray, Jr. seconding. The motion was passed with Dr. Marcus, Dr. Memoli, and Larry Sobel voting against. acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, Coreg CR, labetalol, metoprolol/metoprolol XL, nadolol, pindolol, propranolol/propranolol LA, sotalol, timolol Bystolic, Innopran XL, Levatol, Toprol XL Hypoglycemics, Incretin Mimetics/Enhancers that the recommended change for this class would be the removal of Byetta, Janumet, Januvia, and Symlin as preferred. Dr. Memoli questioned why there were no products recommended as preferred. Chris Andrews cited the ADA treatment module pathway of first line treatment with metformin, then sulfonylurea, insulin, or TZD. He explained that by keeping these products as non-preferred, it would discourage their use as first line treatment. Dr. Sherter expressed concern about entering disease management, especially in a population that is already difficult to treat. Larry Sobel suggested that the committee keep Januvia and Byetta as preferred at the least, with Janumet as an option if it is cost neutral to Januvia plus metformin. Dr. Memoli suggested adding Janumet and Symlin as preferred as well as Januvia and Byetta. Dr. Memoli motioned to reject Provider Synergies recommendations as presented and recommended that the committee accept the recommendation to approve Byetta, Janumet, Januvia, and Symlin as preferred with Larry Sobel seconding. The motion was passed with Richard Carbray, Jr. voting against. Byetta, Janumet, Januvia, Symlin None
5 Hypoglycemics, TZDs that there were no changes recommended. Steve Marcham motioned to approve and accept Provider Synergies recommendations as presented with Dr. Marcus seconding. The motion was passed unanimously. Actoplus Met, Actos, Avandamet, Avandaryl, Avandia Duetact Lipotropics, Other that the recommended changes to this class would be the addition of Fenoglide, Lipofen, and Triglide and the removal of Antara and Zetia. Steve Marcham questioned whether the recommendation to remove Zetia was based more on recent therapeutic reasons or financial reasons. Chris Andrews replied that the financial reasons outweighed the recent therapeutic reasons in his recommendation. Dr. Sherter cited that the overall therapeutic reasons should outweigh the financial reasons and recommended keeping Zetia as preferred. Larry Sobel motioned to approve and accept Provider Synergies recommendations with the addition of Zetia as preferred with Dr. Silberman seconding. The motion was passed unanimously. cholestyramine, colestipol, fenofibrate, Fenoglide, gemfibrozil, Lipofen, Niaspan, Tricor, Triglide, Zetia Antara, Lovaza, niacin (Rx), Welchol Lipotropics, Statins that the recommended change in this class would be the addition of Simcor. Steve Marcham motioned to approve and accept Provider Synergies recommendations as presented with Larry Sobel seconding. The motion was passed unanimously. Caduet, Crestor, Lescol/Lescol XL, Lipitor, lovastatin, pravastatin, Simcor, simvastatin, Vytorin Advicor, Altoprev Multiple Sclerosis Agents that there were no changes recommended for this class. Steve Marcham motioned to approve and accept Provider Synergies recommendations as presented with Dr. Marcus seconding. The motion was passed unanimously. Avonex, Betaseron, Copaxone, Rebif None
6 Other Business: Larry Sobel asked if it was possible to have the country of origin for the medication added to the cost sheets. Chris Andrews replied that it is impossible to know where all components of each medication originate. Chris offered to add the manufacturer for all brand name products in the future. Chris Andrews asked the committee if they would consider adding the sedative hypnotics class to the PDL, or if the class was considered Mental Health Medications. Dr. Marcus replied that this class is not considered Mental Health Medications and the other committee members agreed. The sedative hypnotics will be reviewed at the September meeting. Recommendations for next class reviews: Provider Synergies recommended the following classes be reviewed at the next P&T meeting: Antifungals, Oral Antifungals, Topical Antimigraine Agents Antivirals Bladder Relaxant Preparations BPH Agents Cephalosporins and Related Agents Fluoroquinolones Glucocorticoids, Inhaled Hepatitis C Agents Hypoglycemics, Meglitinides Macrolides/Ketolides Sedative Hypnotics Schedule next meeting: Committee members agreed on Thursday, September 4, 2008 for the next P & T meeting. Meeting adjourned at 7:22pm
Connecticut Medicaid P&T Meeting Minutes June 4, 2009
Connecticut Medicaid P&T Meeting Minutes June 4, 2009 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Eric Einstein, MD Lester Silberman, MD Charles Thompson, MD Peggy Manning
More informationConnecticut Medicaid P&T Meeting Minutes June 3, 2010
The meeting started at 6:30 pm Attendance Connecticut Medicaid P&T Meeting Minutes June 3, 2010 Present Members: Carl Sherter, MD Peggy Manning Memoli, Pharm D Eric Einstein, MD Ezra Griffith, MD Manage
More informationGenerics. Lead with. Prescription Step Therapy Program
Lead with Generics Prescription Step Therapy Program WWW.BCBSLA.COM 04HQ3972 R11/10 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity Company GENERIC DRUGS: A
More informationSave on your drugs with HealthyRx
Save on your drugs with HealthyRx HealthyRx is a savings program offered through the UVa Hoo s Well program. It helps lower your costs on drugs for certain health conditions. Effective 4/1/17, you are
More informationSTATE OF NEW YORK DEPARTMENT OF HEALTH
STATE OF NEW YORK DEPARTMENT OF HEALTH Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237 Antonia C. Novello, M.D., M.P.H., Dr.P.H. Commissioner Dennis P. Whalen
More informationSTATE OF NEW YORK DEPARTMENT OF HEALTH
STATE OF NEW YORK DEPARTMENT OF HEALTH Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237 Antonia C. Novello, M.D., M.P.H., Dr.P.H. Commissioner Dennis P. Whalen
More informationUF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008
UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationConnecticut Medicaid P&T Meeting Minutes March 20, 2008
Connecticut Medicaid P&T Meeting Minutes March 20, 2008 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Bennett Enowitch, MD Charles Thompson, MD Steven Marcham, RPh Lawrence
More information2013 Step Therapy (ST) Criteria
2013 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationConnecticut Medicaid P&T Meeting Minutes September 4, 2008
Connecticut Medicaid P&T Meeting Minutes September 4, 2008 The meeting started at 6:30 pm Attendance Present Members: Carl Sherter, MD Eric Einstein, MD Bennett Enowitch, MD Lester Silberman, MD Hilda
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 6 Jan 2011 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationGenerics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m
Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity
More informationPDF created with pdffactory trial version
We are using more prescription drugs than ever before to manage health conditions and prevent problems. And those drugs are more expensive than ever before. In 2003, prescription drug costs in the United
More informationAnnual Review of Antihypertensives - Fiscal Year 2009
Annual Review of Antihypertensives - Fiscal Year 2009 Oklahoma HealthCare Authority April 2010 Current Prior Authorization Criteria There are 7 categories of antihypertensive medications currently included
More informationValue-Based Drug List for ABCs of Diabetes
Effective January 1, 2019 Value-Based Drug List for ABCs of Diabetes PCPS provides a Value-Based Benefit Design (VBD) to qualified participants in the ABCs of Diabetes. This means you will have lower out-of-pocket
More informationSTEP THERAPY ALGORITHMS PUP Select Formulary
The Step Therapy drug will be dispensed if the drug has been dispensed within 120 days of current fill or if alternative (Step 1) drugs have been used first. If the member s prescription claim fails the
More information2012 Preventive Drug List for Consumer Driven Health Plans Core List
2012 Preventive Drug List for Consumer Driven Health Plans Core List Alphabetical Listing Core List A C E J N Accupril Accuretic acebutolol Aceon Actonel Adalat CC Advicor Afeditab Aggrenox Aldactazide
More informationTRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
More informationANTICHOLINERGIC BRONCHODILATORS ANTICHOLINERGIC BETA-AGONIST COMBO'S CORTICOSTEROID / BRONCHODILATOR COMBO'S NASAL STEROIDS LEUKOTRIENE MODIFIERS
1 of 5 ALLERGY / ASTHMA THERAPIES ANTIHISTAMINES, MINIMALLY SEDATING cetirizine fexofenadine loratadine ANTIHISTAMINE/DECONGESTANT COMBINATIONS cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine
More informationMedicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series
Medicare Shared Savings Program Accountable Care Organization (ACO) Measures Deep Dive Series At Risk Population: Measure 33 Coronary Artery Disease (CAD-7): Angiotensin-Converting Enzyme (ACE) Inhibitor
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More informationAdditional Standard Generics HSA Preventive Drug List Effective January 1, 2019
Additional Standard Generics HSA Preventive Drug List Effective January 1, 2019 Employers can elect to include an additional generic HSA Preventive Drug coverage feature with your prescription benefit
More informationOpioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More informationCardiac Medications At A Glance
Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)
More information2017 Preventive Drug List for Consumer Driven Health Plans Core List
2017 Preventive Drug List for Consumer Driven Health Plans Core List Alphabetical Listing Core List A Accupril Accuretic Acebutolol Aceon Actonel Adalat CC Afeditab Aggrenox Aldactazide Aldactone Alendronate
More information2013 Preventive Drug List for Consumer Driven Health Plans Core List
2013 Preventive Drug List for Consumer Driven Health Plans Core List Alphabetical Listing Core List A C E I M Accupril Accuretic acebutolol Aceon Actonel Adalat CC Advicor Afeditab Aggrenox Aldactazide
More informationTexas Vendor Drug Program. Formulary Drug Index File Layout. Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018
Texas Vendor Drug Program Formulary Drug Index File Layout Layout effective: Jul. 2, 2018 Document update: Oct. 1, 2018 The Vendor Drug Program provides a weekly update of resource data available for download
More informationPassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cardiovascular Drugs Pharmacy Technician Training Systems Passassured, LLC p1 Medication Review, Cardiovascular Drugs Click Here for Glossary Index! Click Here to Print Topic Help File
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET
ARBS DIOVAN HCT 160-12.5 MG TAB, DIOVAN HCT 80-12.5 MG TABLET 30-day trial of a Step 1 drug in the previous 120 days is required. Step 1 Drugs: Losartan, Losartan/HCTZ PAGE 1 LAST UPDATED 05/2016 BILE
More informationSouth Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB
More informationANGIOTENSIN RECEPTOR BLOCKERS
Step Therapy 2014 2 Tier-Alameda Last Updated: 10/10/2014 ANGIOTENSIN RECEPTOR BLOCKERS Benicar Benicar Hct Diovan Valsartan Step 1: First line therapy should be irbesartan, irbesartan/hctz, losartan,
More informationMedications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy
Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Competency for CDE Exam 3.1.A Oral Medications for Type 2 Diabetes
More informationMedications for Type 2 Diabetes CDE Exam Preparation
Medications for Type 2 Diabetes CDE Exam Preparation Medications for Type 2 Diabetes CDE Exam Preparation Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy Agenda Medication
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationDrug Regimen Optimization
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Excluding Valsartan / Ramipril Prior authorization criteria logic: a description
More informationPA Start Date Therapeutic Class P&T Review Date 7/1/13 TOP$ (Single Drug Reviews) include:
Maryland Department of Health and Mental Hygiene PDL Prior Authorization Implementation Schedule PA Start Therapeutic Class P&T Review 7/1/13 5/2/13 Antidepressants, Other (ForfivoXL) COPD Agents (Tudorza
More informationSouth Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call To Order A meeting of the
More informationTexas Vendor Drug Program. Formulary Delimited File Layout. April 26, 2017
Texas Vendor Drug Program Formulary Delimited File Layout April 26, 2017 The Vendor Drug Program provides a weekly update of resource data available for download from txvendordrug.com/resources/downloads.
More information2018 Preventive Drug List for Consumer Driven Health Plans Core List
2018 Preventive Drug List for Consumer Driven Health Plans Core List Alphabetical Listing Core List A Accupril Accuretic Acebutolol Aceon Actonel Adalat CC Afeditab Aggrenox Aldactazide Aldactone Alendronate
More information30. Beta Adrenergic Receptor Blocking Agents Acebutolol Carteolol (Cartrol) February 12, 2003 Penbutolol (Levatol) Propranolol (Inderal LA)
#03-01 Prior Authorization PDL Implementation Schedule UPDATES Drugs on PDL Drugs which Require PA Implementation Date 26. Bone Resorption Suppression Agents Alendronate (Fosamax) Etidronate (Didronel)
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 25 March 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More informationRXSelect SM Preventive Drug List
RXSelect SM Preventive Drug List The prescription drug categories listed in this document are identified as preventive drugs and may be covered at a different benefit level than non-preventive drugs. Prescriptions
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More informationDaiichi Sankyo, Inc. (DSI)
Daiichi Sankyo, Inc. (DSI) Outlook for U.S. Business for 2009 Nov. 7 th, 2007 Joseph P. Pieroni President and CEO Daiichi Sankyo, Inc. Largest Pharmaceutical markets $300 $274.4 Annual Sales (US$ billions)
More informationPreferred Covered Brands (may have a reduced copay)
Preventive Drug List For High-Deductible Health Plans Only effective 1/1/12 For your better health, your employer has added an enhanced benefit to your High-Deductible Health Plan for preventive care drugs.
More informationNovo Nordisk Lilly sanofi aventis
Novo Nordisk Lilly sanofi aventis Announcements TURN OFF CELL PHONES Cell phone police are watching If you need to make a call, leave the room Restrooms Breakroom Low blood sugar Copy of presentation,
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationRxBlue 2010 ST Criteria
RxBlue 2010 ST Criteria ANTIDEPRESSANTS - SARAFEM... 10 FLUOXETINE HCL... 10 SARAFEM... 10 SELFEMRA... 10 ANTIDEPRESSANTS- SSRI, SNRI... 11 CELEXA... 11 CITALOPRAM... 11 CYMBALTA... 11 EFFEXOR XR... 11
More information12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 9/11/2018 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 5/17, 9/15, 2/13, 2/08, LOB
More informationDRUG CLASSIFICATION. Prevention of Cardiovascular Disease
Generic Preventive Care/ Safe Harbor Drug Program List Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition.
More informationPhysician/Clinic Collaborative Practice Agreement
Physician/Clinic Collaborative Practice Agreement Effective October 1, 2010, Connecticut Senate Bill 428 (PA 10-117) extends to all settings and medical conditions the opportunity for licensed pharmacists
More information2019 Preventive Drug List for Consumer Driven Health Plans Core List
Core Drug List 2019 Preventive Drug List for Consumer Driven Health Plans Core List ffective Jan. 1, 2019 This document is a list of Preventive Medications that may be covered under your benefit plan.
More informationClinical Teach-Back Cards
Clinical Teach-Back Cards The Medicare Quality Improvement Organization for Texas TMF Health Quality Institute focuses on improving lives by improving the quality of health care through contracts with
More informationACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease
ACE Inhibitors and ARBs To Protect Your Heart? A Guide for Patients Being Treated for Stable Coronary Heart Disease Is This Guide Right for Me? This Guide Is for You If: You have coronary heart disease,
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationSecretary for Health and Family Services Selections for Preferred Products
Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based
More informationInformation is based on the NCQA 2016 Technical Specifications.
s Provider Tips for Optimizing HEDIS Results Mount Carmel Health Partners wants to help improve your Quality Ratings. These tip sheets offer the key aspects of a specific HEDIS measure as well as useful
More informationValue-Based Benefits MEDICATION LIST. by Therapy Class
Value-Based Benefits MEDICATION LIST by Therapy Class The prescription drug coverage under your Healthy Rewards value-based benefits program is designed to increase adherence to medications used to treat
More informationPreventive medications list
Preventive medications list In addition to a healthy lifestyle, preventive medications can help people avoid many illnesses and conditions. A consumer-directed health (CDH) plan that includes preventive
More informationLisinopril 20 converting to losartan
Search Lisinopril 20 converting to losartan Stop wasting your time with unanswered searches. lisinopril 40 mg to losartan conversion,cannot Find low price Best. Winds SSW at 10 to 20. Lisinopril 20 to
More informationClinical Teach-Back Cards
Clinical Teach-Back Cards The Quality Innovation Network - Quality Improvement Organization (QIN-QIO) for Delaware, Louisiana, New Jersey, Pennsylvania and West Virginia The people at Quality Insights
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
September 2008 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair); Dennis Chapron, M.S.; Richard Gannon, Pharm.D.; Keith Lyke R.Ph., Mike Moore, R.Ph., MPH; Bhupesh Mangla, M.D., Ram
More informationSouth Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call To Order A meeting of the
More informationLiving with Congestive Heart Failure: A Guide to a Healthy Heart
Living with Congestive Heart Failure: A Guide to a Healthy Heart Things to Know, Before You Go Dear Patient/Caregiver These are the things you NEED TO KNOW, BEFORE YOU GO. It is very important that you
More information2018 Step Therapy Criteria
2018 Step Therapy Criteria ANGIOTENSIN RECEPTOR BLOCKERS... 2 ANTIDEPRESSANTS... 3 ANTIDEPRESSANTS, MISCELLANEOUS... 4 ANTIDEPRESSANTS, OTHER... 5 ANTIDIABETIC AGENTS... 6 ANTIGOUT AGENTS... 7 ANTIHYPERTENSIVE
More informationPharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationDrugs That Have Quantitiy Limits (QL)
Drugs That Have Quantitiy Limits (QL) There are Quantity Limits set by your UA Medicare Group Part D Prescription Drug Plan for the drugs listed below. The UA Medicare Group Part D Prescription Drug Plan
More informationDoctor discussion guide:
Doctor discussion guide: MAnaging Cholesterol Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your
More informationAn Integrated Healthcare System s Approach to Chronic Pain
An Integrated Healthcare System s Approach to Chronic Pain Presbyterian Health Plan (PHP) Charles Baumgart M.D., Chief Medical Officer Louanne Cunico PharmD, Pharmacy Director September 20, 2011 Medical
More informationConversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
More informationGeneric Preventive Care/ Safe Harbor Drug Program List
Preventive care/safe harbor drugs are drugs that can help keep you from developing a health condition or related complications of a health condition. The Generic Preventive Care/Safe Harbor Drug Program
More informationCARDIAC IMAGING QUESTIONNAIRE
Date of test: / / Month day year Last name First name Middle initial Street address City State Zip code Home phone ( ) - Work phone ( ) - Cell Phone ( ) - Email: Age: Demographics: What is your ethnicity?
More informationDoctor discussion guide:
Bring this printout to your next doctor s appointment. It will help you and your doctor work together to set goals for treatment, evaluate the success of your treatment, and reduce your risk of side effects.
More informationInformation in these slides is used with permission from St. Mary s Cardiac Rehab
Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure
More informationClinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18
Clinical Policy: Reference Number: CP.PMN.61 Effective Date: 08.01.14 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationBlue Cross KeyRx TK Preventive RX Pack Drug List Large Group Effective January 1, 2019
Blue Cross KeyRx TK Preventive RX Pack Drug List Large Group Effective January 1, 2019 Your employer may have elected to include the KeyRx Turn-Key Preventive Pack Drug List in your benefit plan. Below
More informationPequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
More informationRXSELECT PREVENTIVE PRESCRIPTION DRUG LIST (UTAH)
RXSELECT PREVENTIVE PRESCRIPTION DRUG LIST (UTAH) The prescription drug categories listed in this document are identified as preventive drugs and may be covered at a different benefit level than non-preventive
More informationLisinopril to losartan equivalent
Your browser does not support script 22-11-2011 Specifically, Lisinopril (brand names include Prinivil and Zestril) is the third most-prescribed drug in the US, according to WebMD Health News (April 20.
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationCHAPTER 2. Knowing YOUR MEDICATIONS. Image: istock.com/bakibg. Knowing Your Medications 23
CHAPTER 2 Knowing YOUR MEDICATIONS Knowing Your Medications 23 Image: istock.com/bakibg MEDICATION Prescription medications help your heart get better and protect you from more harm. People who take their
More informationConversion of losartan to lisinopril
Cari untuk: Cari Cari Conversion of losartan to lisinopril Dania Alsammarae, Strategy Director and co-founder of Anglo Arabian Healthcare speaks with Neil Halligan of Arabian Business on what it takes
More informationHypertension, Hyperlipidemia and Obesity. Mi-CCSI
Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these
More informationIntel Connected Care with Providence 2015 Preventive Drug List
Intel Connected Care with Providence 2015 Preventive Drug List Formulary drugs listed below are covered at 100%, not subject to the deductible for the High Deductible Health Plan (HDHP) and Primary Care
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationNOTES: Anemia Medical condition in which the number of red blood cells (the blood count) is reduced.
Advance care planning A process in which you decide what you would like to happen to you, or not happen to you, if you become unable to make decisions about your healthcare treatment or if you are unable
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
December 2012 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Dennis Chapron, M.S., Bhupesh Mangla, M.D., Charles Caley, Pharm.D., Ram Illindala, M.D., Richard
More informationACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR
S/N ME OF MEDICATIONS BRANDED/GENERIC DRUG CLASS * UNIT PRICE RANGE (SGD$) 1 ACEBUTOLOL HCL 100MG CAPSULE SECTRAL BETA BLOCKERS 0.50 2 ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS 0.33 3 ALISKIREN
More informationDeveloped by Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed : October 2009 Most recently updated: September 2011
Developed by Kathy Wonderly RN, BSPA, CPHQ Performance Improvement Coordinator Developed : October 2009 Most recently updated: September 2011 To identify the patients who should receive a beta blocker
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION 1363-M Opioids IR MME Limit and Post Limit This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMedications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.
Medications Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. What do I need to know about medications after my heart attack? When you
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 14 Jan 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 14 Jan 21 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form MEDICA HEALTH PLAN IA EXCHANGE 1362-M Opioids IR Labeling Post Limit (HMF) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationConnecticut Medical Assistance Pharmacy Program Drug Utilization Review (DUR) Program DUR Board Meeting
March 2015 Minutes ATTENDEES Board Members Present: Kenneth Fisher, R.Ph. (Chair), Keith Lyke R.Ph., Bhupesh Mangla, MD, Richard Gannon, Pharm.D., Charles Caley Pharm.D. BCPP, Ram Illindala, MD, Carol
More information/ United HealthCare Services, Inc. Page 1 of 7
Accupril Accuretic Acebutolol Aceon Activella Actonel Adalat CC Advicor Afeditab CR Aggrenox Aldactone Aldomet Aldoril Alendronate Alora Altace Altoprev Amiloride/HCTZ Amlodipine Amlodipine/Benazepril
More informationFirstCarolinaCare Insurance Company Step Therapy Requirements
ANALGESICS, NARCOTICS KADIAN MORPHINE SULFATE ER PRIOR CLAIM FOR MORPHINE SULFATE SUSTAINED ACTION TABLET (MS CONTIN) WITHIN THE PAST 120 DAYS. ANTIBACTERIALS (EENT) BESIVANCE PRIOR CLAIM FOR CIPROFLOXACIN
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG
More information